Today is the last day of trading in Alzinova's warrants of series TO2 2020/2022
Today, 3 February 2022, is the last day of trading for the warrants of series TO2 2020/2022 (the “warrants”) which Alzinova AB (publ) (“Alzinova” or the “Company”) issued in connection with the issue of units with deviation from the shareholders’ pre-emption rights which the Company carried out in October 2020. The warrants are traded on Nasdaq First North Growth Market. Two (2) warrants entitle the holder to subscribe for one (1) new share in Alzinova at a subscription price of SEK 6.50. Upon full exercise of all warrants, Alzinova will receive approximately SEK 26.5 million before issue costs. The exercise period for the warrants runs up to and including 7 February 2022.
Instructions on how to subscribe for shares in Alzinova through the exercise of the warrant can be found in the press release that Alzinova published on 24 January 2022.
Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before 7 February 2022 as different nominees have different processing times.
Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Hagberg Aneborn Fondkomission, no later than 7 February 2022. The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites (www.alzinova.com, www.hagberganeborn.se, www.redeye.se). Please note that payment for the new shares must be received by Hagberg Aneborn no later than 7 February 2022 in accordance with the instructions on the application form.
Please note that warrants that are not exercised on or before 7 February 2022 will expire without value. Holders who do not wish to exercise their warrants may sell them today, 3 February 2022, at the latest.
Investor presentations
Alzinova will present at the Redeye Forum Special: Transactions today, 3 February 2022. Information about the event is available on Redeye's website.
Advisers
Redeye AB acts as financial adviser, Fredersen Advokatbyrå AB acts as legal adviser and Hagberg Aneborn Fondkommission AB acts as the issuing agent in the Rights Issue.
For more information, please contact:
Kristina Torfgård, CEO Alzinova
Tel: +46 70 846 79 75
e-mail: kristina.torfgard@alzinova.com
About Alzinova
Alzinova AB (publ) is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further. The Company’s Certified Advisor on Nasdaq First North Growth Market is Corpura info@corpura.se +46 768-532 822. For more information about Alzinova, please visit: www.alzinova.com